Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 1039
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2012  |  Volume : 1  |  Issue : 4  |  Page : 190-195

The challenge of relapsed/refractory myeloma: An emerging role of bortezomib

1 Department of Pharmacy, Shri JJT University, Rajasthan; Medical Services, Torrent Pharma Ltd., Ahmedabad, India
2 Medical Services, Torrent Pharma Ltd., Ahmedabad, India

Correspondence Address:
Bhargav Vyasa
D/301, Ashutosh Apartments, Ahmedabad-380013
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2278-0513.106247

Rights and Permissions

The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents includes thalidomide and its analogs, proteasome inhibitors, arsenic trioxide, farnesyltransferase inhibitors 2-methoxyestradiol and lenalidomide has extended treatment options and has improved the outcome and quality of life of patients with MM. This review presents the totality of evidence through a systematic review that assessed the efficacy, safety or toxicity of bortezomib in patients with relapsed/refractory myeloma with or without concomitant complications. This review has precisely covered the role of bortezomib in patients with relapsed/refractory myeloma and not the newly detected populace.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded203    
    Comments [Add]    

Recommend this journal